Free Trial

KindlyMD (NASDAQ:NAKA) Stock Price Target Lowered at B. Riley Financial

KindlyMD logo with Finance background
Image from MarketBeat Media, LLC.

Key Points

  • B. Riley cut its KindlyMD price target from $13 to $10 but maintained a Buy rating; the new target implies 100% upside from the prior close.
  • Analyst views remain mixed: MarketBeat reports a “Moderate Buy” consensus and an average $19 target, while one analyst rates the stock Sell.
  • KindlyMD reported quarterly EPS of $4.07, beating estimates of a $0.49 loss, but posted negative revenue of $1.93 million and a deeply negative net margin.
  • Five stocks to consider instead of KindlyMD.

KindlyMD (NASDAQ:NAKA - Get Free Report) had its target price cut by B. Riley Financial from $13.00 to $10.00 in a report issued on Monday, Benzinga reports. The brokerage presently has a "buy" rating on the stock. B. Riley Financial's target price suggests a potential upside of 100.00% from the company's previous close.

A number of other research analysts also recently weighed in on the stock. Wall Street Zen upgraded shares of KindlyMD from a "sell" rating to a "hold" rating in a research report on Saturday. Weiss Ratings reissued a "sell (d-)" rating on shares of KindlyMD in a research note on Wednesday, November 4th. Finally, TD Cowen raised their target price on KindlyMD from $1.00 to $17.00 and gave the company a "buy" rating in a research report on Monday, July 27th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $19.00.

Check Out Our Latest Research Report on KindlyMD

KindlyMD Stock Performance

NAKA opened at $5.00 on Monday. The company has a debt-to-equity ratio of 0.18, a current ratio of 0.23 and a quick ratio of 0.23. The firm has a fifty day moving average price of $7.87 and a 200 day moving average price of $7.52. KindlyMD has a 1 year low of $3.33 and a 1 year high of $25.22. The stock has a market cap of $91.73 million, a P/E ratio of -0.33 and a beta of 16.03.

KindlyMD (NASDAQ:NAKA - Get Free Report) last announced its quarterly earnings results on Friday, November 13th. The company reported $4.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.49) by $4.56. KindlyMD had a negative net margin of 1,067.93% and a negative return on equity of 73.53%. The firm had revenue of ($1.93) million for the quarter. Equities research analysts anticipate that KindlyMD will post -12.94 earnings per share for the current year.

Insider Buying and Selling at KindlyMD

In related news, CEO David F. Bailey purchased 32,134 shares of the firm's stock in a transaction that occurred on Wednesday, August 19th. The shares were purchased at an average cost of $5.59 per share, with a total value of $179,629.06. Following the purchase, the chief executive officer owned 32,134 shares of the company's stock, valued at $179,629.06. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last three months, insiders have bought 41,904 shares of company stock worth $235,231. 24.08% of the stock is owned by corporate insiders.

About KindlyMD

(Get Free Report)

KindlyMD is a Utah-based healthcare company that provides outpatient medical services, with a focus on integrated care. Its offerings include primary care, behavioral health and treatment for substance use disorders, along with care coordination intended to connect patients with appropriate services. The company serves patients through clinics in Utah and has emphasized care for people with complex or ongoing health needs. KindlyMD combined with Nakamoto Holdings in 2025; the resulting company trades on Nasdaq under the symbol NAKA.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in KindlyMD Right Now?

Before you consider KindlyMD, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and KindlyMD wasn't on the list.

While KindlyMD currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines